Cargando…

IL-33/ST2/IL-9/IL-9R Signaling Disrupts Ocular Surface Barrier in Allergic Inflammation

This study was to explore a novel IL-33/ST2/IL-9/IL-9R signaling pathway that disrupts ocular surface barrier and amplifies allergic inflammation. Two murine models of experimental allergic conjunctivitis (EAC) and IL-9 topical challenge in wild type Balb/c and ST2(−/−) mice, and two culture models...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Jiaoyue, Gao, Ning, Zhang, Yun, Chen, Xin, Li, Jinmiao, Bian, Fang, Chi, Wei, Liu, Zuguo, de Paiva, Cintia, Pflugfelder, Stephen C., Li, De-Quan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7572432/
https://www.ncbi.nlm.nih.gov/pubmed/32358573
http://dx.doi.org/10.1038/s41385-020-0288-4
_version_ 1783597340789047296
author Hu, Jiaoyue
Gao, Ning
Zhang, Yun
Chen, Xin
Li, Jinmiao
Bian, Fang
Chi, Wei
Liu, Zuguo
de Paiva, Cintia
Pflugfelder, Stephen C.
Li, De-Quan
author_facet Hu, Jiaoyue
Gao, Ning
Zhang, Yun
Chen, Xin
Li, Jinmiao
Bian, Fang
Chi, Wei
Liu, Zuguo
de Paiva, Cintia
Pflugfelder, Stephen C.
Li, De-Quan
author_sort Hu, Jiaoyue
collection PubMed
description This study was to explore a novel IL-33/ST2/IL-9/IL-9R signaling pathway that disrupts ocular surface barrier and amplifies allergic inflammation. Two murine models of experimental allergic conjunctivitis (EAC) and IL-9 topical challenge in wild type Balb/c and ST2(−/−) mice, and two culture models of primarily human corneal epithelial cells (HCECs) and mouse CD4(+) T cells were performed. Clinical manifestations, Oregon Green Dextran (OGD) staining, the apical junction complexes (AJCs), IL-33/ST2 and IL-9/IL-9R signaling molecules were evaluated in ocular surface and its draining cervical lymph nodes (CLNs) by RT-qPCR, immunostaining and ELISA. The typical allergic signs, enhanced OGD staining intensity, disrupted morphology of AJCs, including ZO-1, claudin 1, occludin and E-cadherin, and the stimulated signaling of IL-33/ST2 and IL-9/IL-9R were observed in ocular mucosa and draining CLNs in EAC-Balb/c mice, but significantly reduced or eliminated in EAC-ST2(−/−) mice. Topical challenge of IL-9 resulted in the obvious OGD staining and disrupted ocular surface AJCs in Balb/c mice and in HCECs in vitro. IL-9 production was found to be stimulated by IL-33 in CD4(+) cells from Balb/c mice in vitro. Our findings uncovered a novel phenomenon and mechanism by which ocular surface barrier integrity is disrupted in allergic conjunctivitis by IL-33/ST2/IL-9/IL-9R signaling pathway, which may amplify the allergic inflammation.
format Online
Article
Text
id pubmed-7572432
institution National Center for Biotechnology Information
language English
publishDate 2020
record_format MEDLINE/PubMed
spelling pubmed-75724322020-11-01 IL-33/ST2/IL-9/IL-9R Signaling Disrupts Ocular Surface Barrier in Allergic Inflammation Hu, Jiaoyue Gao, Ning Zhang, Yun Chen, Xin Li, Jinmiao Bian, Fang Chi, Wei Liu, Zuguo de Paiva, Cintia Pflugfelder, Stephen C. Li, De-Quan Mucosal Immunol Article This study was to explore a novel IL-33/ST2/IL-9/IL-9R signaling pathway that disrupts ocular surface barrier and amplifies allergic inflammation. Two murine models of experimental allergic conjunctivitis (EAC) and IL-9 topical challenge in wild type Balb/c and ST2(−/−) mice, and two culture models of primarily human corneal epithelial cells (HCECs) and mouse CD4(+) T cells were performed. Clinical manifestations, Oregon Green Dextran (OGD) staining, the apical junction complexes (AJCs), IL-33/ST2 and IL-9/IL-9R signaling molecules were evaluated in ocular surface and its draining cervical lymph nodes (CLNs) by RT-qPCR, immunostaining and ELISA. The typical allergic signs, enhanced OGD staining intensity, disrupted morphology of AJCs, including ZO-1, claudin 1, occludin and E-cadherin, and the stimulated signaling of IL-33/ST2 and IL-9/IL-9R were observed in ocular mucosa and draining CLNs in EAC-Balb/c mice, but significantly reduced or eliminated in EAC-ST2(−/−) mice. Topical challenge of IL-9 resulted in the obvious OGD staining and disrupted ocular surface AJCs in Balb/c mice and in HCECs in vitro. IL-9 production was found to be stimulated by IL-33 in CD4(+) cells from Balb/c mice in vitro. Our findings uncovered a novel phenomenon and mechanism by which ocular surface barrier integrity is disrupted in allergic conjunctivitis by IL-33/ST2/IL-9/IL-9R signaling pathway, which may amplify the allergic inflammation. 2020-05-01 2020-11 /pmc/articles/PMC7572432/ /pubmed/32358573 http://dx.doi.org/10.1038/s41385-020-0288-4 Text en http://www.nature.com/authors/editorial_policies/license.html#terms Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Hu, Jiaoyue
Gao, Ning
Zhang, Yun
Chen, Xin
Li, Jinmiao
Bian, Fang
Chi, Wei
Liu, Zuguo
de Paiva, Cintia
Pflugfelder, Stephen C.
Li, De-Quan
IL-33/ST2/IL-9/IL-9R Signaling Disrupts Ocular Surface Barrier in Allergic Inflammation
title IL-33/ST2/IL-9/IL-9R Signaling Disrupts Ocular Surface Barrier in Allergic Inflammation
title_full IL-33/ST2/IL-9/IL-9R Signaling Disrupts Ocular Surface Barrier in Allergic Inflammation
title_fullStr IL-33/ST2/IL-9/IL-9R Signaling Disrupts Ocular Surface Barrier in Allergic Inflammation
title_full_unstemmed IL-33/ST2/IL-9/IL-9R Signaling Disrupts Ocular Surface Barrier in Allergic Inflammation
title_short IL-33/ST2/IL-9/IL-9R Signaling Disrupts Ocular Surface Barrier in Allergic Inflammation
title_sort il-33/st2/il-9/il-9r signaling disrupts ocular surface barrier in allergic inflammation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7572432/
https://www.ncbi.nlm.nih.gov/pubmed/32358573
http://dx.doi.org/10.1038/s41385-020-0288-4
work_keys_str_mv AT hujiaoyue il33st2il9il9rsignalingdisruptsocularsurfacebarrierinallergicinflammation
AT gaoning il33st2il9il9rsignalingdisruptsocularsurfacebarrierinallergicinflammation
AT zhangyun il33st2il9il9rsignalingdisruptsocularsurfacebarrierinallergicinflammation
AT chenxin il33st2il9il9rsignalingdisruptsocularsurfacebarrierinallergicinflammation
AT lijinmiao il33st2il9il9rsignalingdisruptsocularsurfacebarrierinallergicinflammation
AT bianfang il33st2il9il9rsignalingdisruptsocularsurfacebarrierinallergicinflammation
AT chiwei il33st2il9il9rsignalingdisruptsocularsurfacebarrierinallergicinflammation
AT liuzuguo il33st2il9il9rsignalingdisruptsocularsurfacebarrierinallergicinflammation
AT depaivacintia il33st2il9il9rsignalingdisruptsocularsurfacebarrierinallergicinflammation
AT pflugfelderstephenc il33st2il9il9rsignalingdisruptsocularsurfacebarrierinallergicinflammation
AT lidequan il33st2il9il9rsignalingdisruptsocularsurfacebarrierinallergicinflammation